Oramed Pharmaceuticals - ORMP Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORMP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORMP, but not buy additional shares or sell existing shares.
View ORMP analyst ratings or view top-rated stocks.

3 brokers have issued 1-year target prices for Oramed Pharmaceuticals' stock. Their ORMP share price forecasts range from $3.00 to $35.00. On average, they expect the company's stock price to reach $19.00 in the next year. This suggests a possible upside of 779.6% from the stock's current price.
View analysts price targets for ORMP or view top-rated stocks among Wall Street analysts.

Oramed Pharmaceuticals' stock was trading at $12.03 at the beginning of 2023. Since then, ORMP shares have decreased by 82.0% and is now trading at $2.16.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our ORMP earnings forecast.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Monday, January, 10th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.06. The biotechnology company earned $0.67 million during the quarter, compared to the consensus estimate of $0.70 million. Oramed Pharmaceuticals had a negative net margin of 1,353.35% and a negative trailing twelve-month return on equity of 23.62%.

ETFs with the largest weight of Oramed Pharmaceuticals (NASDAQ:ORMP) stock in their portfolio include BlueStar Israel Technology ETF (ITEQ).Invesco Nasdaq Future Gen 200 ETF (QQQS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Oramed Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Millennium Management LLC (1.25%), JPMorgan Chase & Co. (1.03%), Lindbrook Capital LLC (0.98%), Morgan Stanley (0.81%), Susquehanna International Group LLP (0.00%) and Citigroup Inc. (0.17%). Insiders that own company stock include Kevin Rakin, Michael Rabinowitz, Nadav Kidron and Yadin Rozov.
View institutional ownership trends.

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ORMP stock can currently be purchased for approximately $2.16.

Oramed Pharmaceuticals (NASDAQ:ORMP) has a market capitalization of $85.92 million and generates $2.70 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The official website for the company is www.oramed.com. The biotechnology company can be reached via phone at (844) 967-2633, via email at ir@oramed.com, or via fax at 972-2566-0004.